Open AccessAmyotrophic lateral sclerosis: pathogenetic mechanisms and new approaches to pharmacotherapy (literature review)
Author(s) -
Т. М. Алексеева,
Т. Р. Стучевская,
В. С. Демешонок
Publication year - 2019
Publication title -
nervno-myšečnye bolezni
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.139
H-Index - 3
eISSN - 2413-0443
pISSN - 2222-8721
DOI - 10.17650/2222-8721-2018-8-4-12-18
Subject(s) - riluzole , amyotrophic lateral sclerosis , medicine , pharmacotherapy , disease , clinical trial , food and drug administration , edaravone , intensive care medicine , pharmacology , pathology , psychiatry
Amyotrophic lateral sclerosis is a neurodegenerative disease, resulting in the loss of self-service and death of the middle-aged and elderly people. In the last 2 decades, significant progress has been made in the study of the pathogenesis of this disease. Two known drugs (riluzole and edaravone) have been approved by the Food and Drug Administration for treatment of amyotrophic lateral sclerosis. The efficacy of these drugs is extremely low, so clinical trials of new drugs are ongoing all over the world. This review discusses the current achievements and future directions of therapy of this disease.